Delivery Order SPE2DB20D1100-SPE2DB25FD8F3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Gel-One 30 mg/3 ml syringes with a ceiling value of $14,596.00 and an ultimate completion date of September 11, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for a pharmaceutical product to be performed at the contractor's location in Conshohocken, Pennsylvania. Gel-One is a viscosupplement injection used...
- The Defense Logistics Agency awarded a delivery order valued at $10,947.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes on July 28, 2025, with completion scheduled for August 18, 2025. This firm fixed-price delivery order, placed under a competitive procurement with no set-aside designation, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. Gel-One is a viscosupplementation product used primarily for joint pain management,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Gel-One 30 mg/3 mL syringes with a ceiling value of $10,947.00 and ultimate completion date of October 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. Gel-One is...
- The Defense Logistics Agency's Medical Supply Chain awarded a $10,947 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes (3 mL units) on September 4, 2025, with completion targeted for September 25, 2025. This non-competitive delivery order was issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Gel-One 30 mg/3 mL syringes with a ceiling value of $1,459.60. This competitively awarded, firm fixed-price delivery order is classified as a child contract and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement. The product will be performed at the company's headquarters location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $7,298.00 to AmerisourceBergen Drug Corp for the supply of Gel-One 30 mg/3 mL syringes on a firm fixed-price basis. The contract, issued on September 4, 2025, with completion targeted for September 25, 2025, represents a non-competitive set-aside delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,649.00 delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on September 9, 2025, with completion targeted for September 30, 2025. This non-set-aside, competitively awarded contract reflects a firm fixed-price arrangement for pharmaceutical supply delivery to support federal medical procurement needs. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $18,245 delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes on August 7, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The company, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Gel-One 30 mg/3 ml syringes with a ceiling value of $3,649.00. The contract is firm fixed price with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gel-One 30 mg/3 mL syringes, with a ceiling value of $6,203.30 under a firm fixed-price contract. The award, issued on June 20, 2025, with an ultimate completion date of July 14, 2025, represents a non-set-aside, competitively awarded procurement. Performance will be executed from the company's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD8F3Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $18,245 for Gel-One 30 mg/3 mL syringes on August 4, 2025, with completion expected by August 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Gel-One is a viscosupplement injection used primarily for knee osteoarthritis treatment, representing a specialized medical supply within the broader pharmaceutical procurement portfolio that DLA manages for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen maintains a comprehensive global pharmaceutical support vehicle enabling supply of medications, vaccines, medical devices, and specialty healthcare commodities to support military healthcare programs worldwide. The company's extensive federal contract portfolio demonstrates consistent capability to fulfill competitive federal medical procurement requirements across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.2k | 8/4/25 |